Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
29 Noviembre 2023 - 8:00AM
Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company
specializing in physician-dispensed skincare, today announced that
they have signed a licensing agreement with Yuva Biosciences, Inc.
to research and develop means to incorporate Yuva Bioscience’s
mitochondrial research with ELEVAI’s PREx™ (Precision Regenerative
Exosome Technology™) to potentially develop topical skincare
formulations that combine mitochondrial biology with Elevai’s human
umbilical mesenchymal stem cell derived exosomes.
Elevai currently markets its proprietary ELEVAI
E-Series which are peri-procedure topical exosome skincare
products. Yuva Biosciences utilizes mitochondrial science to
address signs of aging of hair, scalp, and skin. Yuva Biosciences
has built a platform that includes a leading-edge AI model to
rapidly screen huge numbers of natural compounds for their
effectiveness in improving mitochondrial health.
“We are excited to partner with Yuva Biosciences
in order to begin research and development of products that may
incorporate the power of mitochondrial technology to further
advance the potential of Elevai exosomes to address cosmetic skin
and hair concerns associated with signs of aging,” said Jordan R.
Plews PhD and CEO of ELEVAI Labs.
“YuvaBio, in partnership with Elevai, is
researching topical cosmetic applications that may limit the
appearance of human aging and we believe this research and
development partnership has the potential to commercialize new
cosmetics not found elsewhere,” commented Keshav K. Singh, PhD,
Scientific Founder of Yuva Biosciences.
About ELEVAI Labs
ELEVAI Labs Inc. is a medical aesthetics company
developing cutting-edge physician-dispensed skin care applications.
The company solves unmet needs in the medical aesthetics space
through a combination of cutting-edge science-driven and
next-generation consumer applications. ELEVAI Labs develops topical
aesthetic skin care cosmetic products for the physician-dispensed
market, with a focus on leveraging a proprietary stem cell exosome
technology. For more information visit www.elevaiskincare.com.
About Yuva Biosciences
Yuva Biosciences is an anti-aging company
harnessing the cutting edge of mitochondrial science to develop
cosmeceuticals as well as pharmaceuticals targeted at aging-related
hair loss, wrinkled skin, and multiple other aging-related
conditions. The Company’s Scientific Founder and Chief Scientific
Advisor, Keshav K. Singh, Ph.D., is a world leader in the field of
mitochondrial biology and genetics and its role in health, disease,
and aging. Dr. Singh is the Joy and Bill Harbert Endowed Chair and
Professor of Genetics, Pathology and Dermatology at the University
of Alabama at Birmingham, and the founding editor-in-chief of the
Mitochondrion journal published by Elsevier. Yuva Biosciences is
headquartered in Birmingham, Alabama. For more information visit
www.yuvabio.com.
Forward-Looking Statements
Certain statements made in this press release
are "forward-looking statements'' within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", "expect", "estimate",
"plan", "outlook", and "project" and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
reflect the current analysis of existing information and are
subject to various risks and uncertainties. As a result, caution
must be exercised in relying on forward looking statements. Due to
known and unknown risks, actual results may differ materially from
the Company’s expectations or projections. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: (i) the
failure to meet projected research & development and production
targets; (ii) changes in applicable laws or regulations; and (iii)
other risks and uncertainties described herein, as well as those
risks and uncertainties discussed from time to time in other
reports and other public filings with the Securities and Exchange
Commission (the "SEC"). These statements are subject to
uncertainties and risks including, but not limited to, the
uncertainties related to market conditions and the completion of
the initial public offering on the anticipated terms or at all, and
other factors discussed in the “Risk Factors” section of the
registration statement filed with the SEC. The Company’s SEC
filings are available publicly on the SEC’s website at www.sec.gov.
Any forward-looking statement made by us in this press release is
based only on information currently available to the Company and
speaks only as of the date on which it is made. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise, except as required by law.
Media ContactBrenda BuechlerChief Marketing
Officercontact@elevailabs.com
Investor RelationsIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Elevai Labs (NASDAQ:ELAB)
Gráfica de Acción Histórica
De May 2023 a May 2024